Generative AI designed 16 phage genomes that work

Evo and Evo2, generative AI models, designed 16 bacteriophage genomes that replicated and functioned in lab tests, per an August 6 paper in Science.

That's the first full viral genome AI has designed end to end and proven to work in a lab. The authors flag custom phage therapy for antibiotic-resistant infections as the near-term payoff, since all 16 genomes target bacteria, not human cells.

Biosecurity researchers are using the result differently, as a case study for tightening DNA-synthesis screening. Right now, screening checks the sequence someone orders. Researchers want it to check the identity of the orderer too, a category of screening the push itself implies providers don't do consistently now.

Sixteen working phages is the headline. The sharper point is that genome-design capability moved faster than the rule meant to gate who can order synthetic DNA. This paper proves the capability works. It doesn't require a single synthesis provider to change how they screen orders.

Published August 6, the paper gave biosecurity researchers their case study for the screening push. Watch whether synthesis companies add identity screening on their own, or wait for a law to force it after a bad order gets filled.